Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 5/2017

01-05-2017 | Original Paper

Awareness and Willingness to Use Pre-exposure Prophylaxis (PrEP) Among Men Who Have Sex with Men and Transgender Women in Brazil

Authors: Brenda Hoagland, Raquel B. De Boni, Ronaldo I. Moreira, José Valdez Madruga, Esper G. Kallas, Silvia Pereira Goulart, Natalia Cerqueira, Thiago S. Torres, Paula M. Luz, Nilo Martinez Fernandes, Albert Y. Liu, Beatriz Grinsztejn, Valdilea G. Veloso, For the PrEP Brasil Study Team

Published in: AIDS and Behavior | Issue 5/2017

Login to get access

Abstract

Antiretroviral pre-exposure prophylaxis (PrEP) is recommended to prevent HIV infection among high-risk men who have sex with men (MSM) though not available in Brazil where the HIV epidemic persists unabated in this group. This cross-sectional study describes PrEP awareness and willingness and associated factors among MSM and transvestite/transgender women (trans women) pre-screened for the PrEP Brasil study. Awareness was reported by 61.3 % of the participants and was associated with age, education, site, study period and prior HIV testing. Most participants (82.1 %) were willing to use PrEP, which was associated with site, study period, number of male condomless anal sexual partners and anal sex with HIV positive/unknown partners. PrEP information is need among young and less educated individuals. Willingness to use PrEP was high and future studies should be conducted to confirm PrEP acceptability and the characteristics of the population who chose to adopt this intervention.
Literature
1.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral
2.
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral
3.
Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.CrossRefPubMed
4.
Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083–90.CrossRefPubMed
5.
Mccormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Articles pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53–60.CrossRefPubMedPubMedCentral
6.
Molina J-M, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.CrossRefPubMed
7.
Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. JAIDS. 2009;50:77–83.PubMedPubMedCentral
8.
Barash EA, Golden M. Awareness and use of HIV pre-exposure prophylaxis among attendees of a seattle gay pride event and sexually transmitted disease clinic. AIDS Patient Care STDS. 2010;24:689–91.CrossRefPubMed
9.
Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLoS One. 2012;7(1):e28238.CrossRefPubMedPubMedCentral
10.
Wheelock A, Eisingerich AB, Ananworanich J, Gomez GB, Hallett TB, Dybul MR, et al. Are Thai MSM willing to take PrEP for HIV prevention? An analysis of attitudes, preferences and acceptance. PLoS One. 2013;8:e54288.CrossRefPubMedPubMedCentral
11.
Bil JP, Davidovich U, van der Veldt WM, Prins M, de Vries HJC, Sonder GJB, et al. What do Dutch MSM think of preexposure prophylaxis to prevent HIV-infection? A cross-sectional study. AIDS. 2015;29:955–64.CrossRefPubMed
12.
De Boni RB, Veloso V, Grinsztejn B. The epidemiology of HIV in Latin America and the Caribbean. Curr Opin HIV AIDS. 2014;9(2):192–8.CrossRefPubMed
13.
Kerr LRFS, Mota RS, Kendall C, Pinho ADA, Mello MB, Guimarães MDC, et al. HIV among MSM in a large middle-income country. AIDS. 2013;27:427–35.CrossRefPubMed
14.
Departamento de DST Aids e Hepatites Virais. Boletim Epidemiologico—Aids e DST. Brasilia: Ministerio da Saúde; 2015.
15.
Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13:214–22.CrossRefPubMed
16.
Martins TA, Kerr LRFS, Macena RHM, Rosa S, Carneiro KL, Gondim RC, et al. Travestis, an unexplored population at risk of HIV in a large metropolis of northeast Brazil: a respondent-driven sampling survey. AIDS Care. 2013;25:606–12.CrossRefPubMed
17.
Brandelli A, Anna C, Vaitses M, Michelle F, Jacinto M, Filho R, et al. Population-based HIV prevalence and associated factors in male-to-female transsexuals from southern Brazil. Arch Sex Behav. 2015;44:521–4.CrossRef
18.
Saúde M, De Vigilância S, Girade R, Costa AR. Protocolo Clínico e Diretrizes; 2013.
19.
Silva DS, De BoniRB, Lake JE, Cardoso SW, Ribeiro S, Moreira RI, et al. Retention in early care at an HIV outpatient clinic in Rio de. AIDS Behav. 2015. doi:10.​1007/​s10461-015-1235-3.
20.
Grinsztejn B, Luz PM, Pacheco AG, Santos DVG, Velasque L, Moreira RI, et al. Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era. PLoS One. 2013;8:e59768.CrossRefPubMedPubMedCentral
21.
Cohen SE, Vittinghoff E, Bacon O, Doblecki-Lewis S, Postle BS, Feaster DJ, et al. High interest in pre-exposure prophylaxis among men who have sex with men at risk for HIV-infection: baseline data from the US PrEP demonstration project. JAIDS. 2015;68(4):439–48.PubMedPubMedCentral
22.
Yang D, Chariyalertsak C, Wongthanee A, Kawichai S, Yotruean K, Saokhieo P, et al. Acceptability of pre-exposure prophylaxis among men who have sex with men and transgender women in northern Thailand. PLoS One. 2013;8(10):e76650.CrossRefPubMedPubMedCentral
23.
Bassichetto KC, Bergamaschi DP, Oliveira SM, Deienno MCV, Bortolato R, de Rezende HV, et al. Elevated risk for HIV-1 infection in adolescents and young adults in São Paulo, Brazil. PLoS One. 2008;3(1):e1423.CrossRefPubMedPubMedCentral
24.
Zhou F, Gao L, Li S, Li D, Zhang L, Fan W, et al. Willingness to accept HIV pre-exposure prophylaxis among Chinese men who have sex with men. PLoS One. 2012;7:e32329.CrossRefPubMedPubMedCentral
25.
Krakower DS, Mimiaga MJ, Rosenberger JG, Novak DS, Mitty JA, White JM, et al. Limited awareness and low immediate uptake of pre-exposure prophylaxis among men who have sex with men using an internet social networking site. PLoS One. 2012;7(3):e33119.CrossRefPubMedPubMedCentral
26.
Sineath RC, Finneran C, Sullivan P, Sanchez T, Smith DK, Van GriensvenF, et al. Knowledge of and interest in using preexposure prophylaxis for HIV prevention among men who have sex with men in Thailand. J Int Assoc Provid AIDS Care. 2013;12(4):227–31.CrossRefPubMed
27.
Holt M, Murphy DA, Callander D, Ellard J, Rosengarten M, Kippax SC, et al. Willingness to use HIV pre-exposure prophylaxis and the likelihood of decreased condom use are both associated with unprotected anal intercourse and the perceived likelihood of becoming HIV positive among Australian gay and bisexual men. Sex Transm Infect. 2012;88:258–63.CrossRefPubMed
28.
Aghaizu A, Mercey D, Copas A, Johnson AM, Hart G, Nardone A. Who would use PrEP? Factors associated with intention to use among MSM in London: a community survey. Sex Transm Infect. 2013;89:207–11.CrossRefPubMed
29.
Lebouché B, Engler K, Machouf N, Lessard D, Thomas R. Predictors of interest in taking pre-exposure prophylaxis among men who have sex with men who used a rapid HIV-testing site in Montreal (Actuel sur Rue). HIV Med. 2016;17:152–8.CrossRefPubMed
30.
Mascena MADS, Gabriela V, Calazans J. High HIV prevalence among men who have sex with men São Paulo, Brazil in a time-location sampling survey. AIDS Behav. 2015;19:1589–98.CrossRef
31.
32.
Bavinton BR, Jin F, Prestage G, Zablotska I, Grinsztejn B, Phanuphak N, et al. Viral load awareness and risk behaviour in male serodiscordant couples in Australia, Brazil and Thailand. IAS. Vancouver; 2015. p. 141.
33.
Grant RM, Koester KA. What people want from sex and preexposure prophylaxis. Curr Opin HIV AIDS. 2016;11:3–9.CrossRefPubMed
34.
Ware NC, Wyatt MA, Haberer JE, Baeten JM, Kintu A, Psaros C, et al. What’ s love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. JAIDS. 2012;59:463–8.PubMed
35.
Escudero DJ, Kerr T, Operario D, Socías ME, Sued O, Marshall BDL. Inclusion of trans women in pre-exposure prophylaxis trials: a review. AIDS Care. 2015;27:637–41.CrossRefPubMed
36.
Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, et al. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV. 2015;2:e512–9.CrossRefPubMedPubMedCentral
37.
Carlo Hojilla J, Koester KA, Cohen SE, Buchbinder S, Ladzekpo D, Matheson T, et al. Sexual behavior, risk compensation, and HIV prevention strategies among participants in the San Francisco PrEP demonstration project: a qualitative analysis of counseling notes. AIDS Behav. 2015;20:1461–9.CrossRef
38.
Mugwanya KK, Donnell D, Celum C, Thomas KK, Ndase P, Mugo N, et al. Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis. 2013;13:1021–8.CrossRefPubMedPubMedCentral
39.
Brooks RA, Landovitz RJ, Kaplan RL, Lieber E, Lee S-J, Barkley TW. Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study. AIDS Patient Care STDS. 2012;26:87–94.CrossRefPubMedPubMedCentral
40.
Liu A, Cohen S, Follansbee S, Cohan D, Weber S, Sachdev D, et al. Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco. PLoS Med. 2014;11(3):1–6.CrossRef
41.
Blumenthal J, Jain S, Krakower D, Sun X, Young J, Mayer K. Knowledge is power! Increased provider knowledge scores regarding pre-exposure prophylaxis (PrEP) are associated with higher rates of PrEP prescription and future intent to prescribe PrEP. AIDS Behav. 2015;19:802–10.CrossRef
42.
Smith DK, Herbst JH, Rose CE. Estimating HIV protective effects of method adherence with combinations of preexposure prophylaxis and condom use among African American men who have sex with men. Sex Transm Dis. 2015;42:88–92.CrossRefPubMed
43.
Calabrese SK, Underhill K. How stigma surrounding the use of HIV preexposure prophylaxis undermines prevention and pleasure: a call to destigmatize “truvada whores”. Am J Public Health. 2015;105:1960–4.CrossRefPubMedPubMedCentral
44.
Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14:820–9.CrossRefPubMed
45.
46.
Young I, Mcdaid L. How acceptable are antiretrovirals for the prevention of sexually transmitted HIV? A review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention. 2014;195–216.
Metadata
Title
Awareness and Willingness to Use Pre-exposure Prophylaxis (PrEP) Among Men Who Have Sex with Men and Transgender Women in Brazil
Authors
Brenda Hoagland
Raquel B. De Boni
Ronaldo I. Moreira
José Valdez Madruga
Esper G. Kallas
Silvia Pereira Goulart
Natalia Cerqueira
Thiago S. Torres
Paula M. Luz
Nilo Martinez Fernandes
Albert Y. Liu
Beatriz Grinsztejn
Valdilea G. Veloso
For the PrEP Brasil Study Team
Publication date
01-05-2017
Publisher
Springer US
Published in
AIDS and Behavior / Issue 5/2017
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1516-5

Other articles of this Issue 5/2017

AIDS and Behavior 5/2017 Go to the issue

Original Paper

Correlates of Enhanced Sexual Pleasure from Condom Use: A Study of Young Black Men Who Have Sex with Men in the United States

Original Paper

Exploring Patterns of Awareness and Use of HIV Pre-Exposure Prophylaxis Among Young Men Who Have Sex with Men

Original Paper

Awareness and Acceptability of Pre-exposure HIV Prophylaxis Among Men Who have Sex with Men in Baltimore

Original Paper

Affect and Condom Use Among Men Who have Sex with Men: A Daily Diary Study

Original Paper

What Messages are Adolescent Voluntary Medical Male Circumcision (VMMC) Clients Getting and How? Findings From an Observational Study in Tanzania

Original Paper

Stigma and Conspiracy Beliefs Related to Pre-exposure Prophylaxis (PrEP) and Interest in Using PrEP Among Black and White Men and Transgender Women Who Have Sex with Men
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits